CurrentCapital BluecrossPolicy AHS - G2051 - Bone Turnover Markers Testing, 1

Bone Turnover Markers Testing

Defines coverage criteria and limitations for measurement of bone turnover markers (BTMs) for individuals with osteoporosis and other conditions, including recommended timing intervals for monitoring during bisphosphonate therapy and exclusions (e.g., teriparatide monitoring, diagnostic use). Also lists marker types and summarizes guideline/evidence background.

Policy Summary

PayerCapital Bluecross

PolicyBone Turnover Markers Testing

Policy CodePolicy AHS - G2051 - Bone Turnover Markers Testing, 1

Change TypeNo material change

Effective DateSep 18, 2015

Next Review Date

Key ActionDocument diagnosis of osteoporosis and therapy status (about to begin or actively being treated with bisphosphonates) and intended purpose when ordering BTMs.

POLICY UPDATE CHANGES

No material clinical or coverage changes in this update.

3Primary coverage positions (covered vs not covered categories)

5CPT codes listed

multipleEvidence references cited

Coverage Summary

Coverage summary: This policy (AHS - G2051) is CURRENT and defines mixed coverage for measurement of bone turnover markers (BTMs) in individuals with osteoporosis. It MEETS COVERAGE CRITERIA for BTMs when ALL of the following apply: the individual has osteoporosis and is about to begin or is actively being treated with bisphosphonates, testing is intended to assess compliance with bisphosphonate therapy or for fracture risk prediction, and testing is performed at specified intervals (baseline before initiation; every 3 months after initiation or change of therapy during the first year; and every 2 years when no medication changes have occurred).

Provider Actions

Documentation Required

Indication documentation for bisphosphonate monitoring

Document the individual’s diagnosis of osteoporosis, current therapy status (about to begin or actively being treated with bisphosphonates), and the intended purpose for ordering bone turnover markers (assess compliance with bisphosphonate therapy or for fracture risk prediction).

Diagnosis: osteoporosis
Therapy status: about to begin or actively being treated with bisphosphonates
Intended purpose: assess compliance with bisphosphonate therapy or fracture risk prediction

Billing Rule

Interval requirements for covered monitoring

Report and schedule testing consistent with the policy's allowed monitoring intervals for bisphosphonate-treated individuals.

Baseline: establish levels before initiating bisphosphonate treatment
Every 3 months: after initiation or change of therapy for the first year
Every 2 years: when no medication changes have occurred

Denial Risk

Excluded indications - denial risk

Claims for bone turnover marker testing to monitor teriparatide treatment, for use as a diagnostic test for osteoporosis, or to manage other conditions with high bone turnover (outside the covered bisphosphonate monitoring scenario) do not meet coverage criteria and may be denied.

Monitoring teriparatide treatment — not covered
Diagnostic use to diagnose osteoporosis — not covered
Management of other high bone-turnover conditions (outside covered scenario) — not covered

Documentation Required

Consideration of bone density and risk factors

When interpreting bone turnover marker results, use them in conjunction with bone density (BMD) measurements and other fracture risk factors; the policy lists preferred and applicable assay codes for reference.

82523
83500
83505
83937
84080

Documentation Required

Laboratory test selection and validation

Laboratories performing assays must validate laboratory-developed tests (LDTs) and comply with CLIA '88 high-complexity laboratory regulations. The policy notes that several bone turnover marker tests have FDA 510(k) clearance and lists examples of cleared assays.

LDTs must be validated and performed in-house under CLIA '88 as high-complexity tests
FDA 510(k)-cleared assays are available (examples listed in policy text)

Background & Evidence

Clinical context: Bone turnover markers (BTMs) are biochemical markers of bone formation and resorption proposed to help predict fracture risk, rate of bone loss, and to monitor response or adherence to osteoporosis therapies. Preferred markers for clinical use are the formation marker PINP (P1NP) and the resorption marker CTX (serum C-terminal telopeptide).

Analytical variability and limited standardization constrain clinical use: biologic and pre-analytical factors (age, sex, circadian rhythm, food, exercise, etc.) and inter-laboratory assay variability result in substantial coefficients of variation and uncertainty in interpreting change. Efforts to standardize sample handling and harmonize assays (national and international working groups) are ongoing but not fully resolved.

Guidelines: Multiple professional societies provide conditional/limited support — many endorse use of PINP and CTX for selected monitoring purposes (for example, assessing adherence, early response to therapy, or monitoring offset after stopping bisphosphonates) but do not support routine use of BTMs for diagnosis of osteoporosis. Overall guidance is mixed: BTMs may be useful in selected situations but are not recommended as routine diagnostic tests.

Key evidence bullets

associationModest but significant association between BTMs (PINP, CTX) and fracture risk (examples: GR/hazard ratios ~1.18-1.28 depending on marker and study)

analytical_variabilityHigh analytical and biological variability: inter- and intra-laboratory CVs vary widely (examples: serum NTX long-term CV ~7.5% vs urinary NTX ~15.6%; lab CVs for markers reported from ~6% up to >40%)

evidence_referencesMultiple peer‑reviewed studies and guidelines cited (references include meta-analyses and guidance from UpToDate, Endocrine Society, IOF/IFCC, ISCD, ESCEO, NAMS, ROS; numbered references 1–44+ in policy)

Definitions:

• BTMs — Bone turnover markers: biochemical markers of bone formation or resorption.

• PINP / P1NP — Procollagen type I N propeptide, a bone formation marker (preferred formation marker for clinical monitoring).

• CTX — C-terminal cross-linked telopeptide of type I collagen, a bone resorption marker (preferred resorption marker for clinical monitoring).

• LDT — Laboratory-developed test: assays developed and validated in-house by clinical laboratories and regulated under CLIA '88 as high-complexity tests (not FDA-cleared).

• FDA 510(k) — Premarket notification clearance pathway for medical devices/tests; several BTM assays have received FDA 510(k) clearance.

• LSC — Least Significant Change: the threshold for a change in a marker considered greater than analytic/biologic variability (used to interpret meaningful changes in BTMs).

Regulatory status of assays: Several bone turnover marker tests have received FDA 510(k) clearance (examples listed in the policy), while many laboratories perform laboratory-developed tests (LDTs) that are validated and regulated under CLIA '88 as high-complexity tests but are not FDA-approved or FDA-cleared.

OpenPayer

Bone Turnover Markers Testing

Coverage Summary

Medical-Necessity Criteria

Coding

Provider Actions

Background & Evidence

82523	Collagen cross links, any method
83500	Hydroxyproline; free
83505	Hydroxyproline; total
83937	Osteocalcin (bone gla protein)
84080	Phosphatase, alkaline; isoenzymes